Effects of statins on blood pressure: A review of the experimental and clinical evidence

Current Vascular Pharmacology

Volumn 5, Issue 2, 2007, Pages 155-161

  Sarafidis, Pantelis A ^a   Kanaki, Angeliki I ^a   Lasaridis, Anastasios N ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Blood pressure; HMG CoA reductase inhibitors; Hypertension; Statins

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MONOTHERAPY; NONHUMAN; OBESITY; PROTEINURIA; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; DRUG EFFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 34247869787     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107780368307     Document Type: Review

References (70)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
2. Mason JC. Statins and their role in vascular protection. Clin Sci 2003; 105: 251-66.
3. Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hyper-cholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am J Nephrol 2000; 20: 12-17.
4. Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000; 16: 139-46.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998; 279: 1615-22.
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
9. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X, et al. Effects of atorvastatin on glucose homeostasis, post-prandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003; 20: 743-5.
10. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287: 598-605.
11. Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995; 44: 212-7.
12. Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 2004; 27: 199-203.
13. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196-201.
14. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
15. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-68.
16. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19: 103-9.
17. Li N, Sawamura M, Nara Y, Kizawa K, Ikeda K, Usui H, et al. HMG-CoA reductase inhibitor affects blood pressure and vascular reactivity. Clin Exp Pharmacol Physiol Suppl 1995; 22: 316-7.
18. Ledingham JM, Laverty R. Fluvastatin remodels resistance arteries in genetically hypertensive rats, even in the absence of any effect on blood pressure. Clin Exp Pharmacol Physiol 2002; 29: 931-4.
19. Kansui Y, Fujii K, Goto K, Abe I, Iida M. Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats. Clin Exp Pharmacol Physiol 2004; 31: 354-9.
20. Oubina MP, de las Heras N, Cediel E, Sanz-Rosa D, Aragoncillo P, Diaz C, et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003; 105: 655-62.
21. Hayashi A, Suzuki M, Ogawa Y, Sonoda R, Sasamata M. Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat. J Pharm Pharmacol 2004; 56: 893-8.
22. Loch D, Levick S, Hoey A, Brown L. Rosuvastatin attenuates hypertension-induced cardiovascular remodelling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2006; 47: 396-404.
23. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30: 968-74.
24. Gross V, Schneider W, Schunck WH, Mervaala E, Luft FC. Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. J Am Soc Nephrol 1999; 10: 1430-9.
25. Regrigny O, Atkinson J, Capdeville-Atkinson C, Liminana P, Chillon JM. Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats. Hypertension 2000; 35: 1105-10.
26. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
27. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21: 379-86.
28. Ge CJ, Hu SJ, Wu YS, Chen NY. Effects of atorvastatin on vascular remodelling in spontaneously hypertensive rats. J Zhejiang Univ Sci 2003; 4: 612-5.
29. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44: 186-90.
30. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31: 225-31.
31. Kido M, Ando K, Oba S, Fujita T. Renoprotective effect of pravastatin in salt-loaded Dahl salt-sensitive rats. Hypertens Res 2005; 28: 1009-15.
32. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003; 42: 1091-7.
33. Sicard P, Lauzier B, Oudot A, Busseuil D, Collin B, Duvillard L, et al. A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats. Arch Mal Coeur Vaiss 2005; 98: 804-8.
34. Antonicelli R, Onorato G, Pagelli P, Pierazzoli L, Paciaroni E. Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther 1990; 12: 165-71.
35. Morgan T, Anderson A, McDonald P, Hopper J, Macaskill G. Simvastatin in the treatment of hypercholesterolemia in patients with essential hypertension. J Hypertens Suppl 1990; 8: 25-30.
36. Sartor G, Katzman P, Eizyk E, Kalen J, Nilsson A, Ugander L, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther 1995; 33: 3-6.
37. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-7.
38. Danaoglu Z, Kultursay H, Kayikcioglu M, Can L, Payzin S. Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients. Anadolu Kardiyol Derg 2003; 3: 331-7.
39. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A; Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-92.
40. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 1993; 71: 82-7.
41. Sung BH, Izzo JL Jr, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997; 10: 592-9.
42. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG, Louis WJ. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994; 3: 404-6.
43. Glorioso N, Troffa C, Filigheddo F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6.
44. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y, et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004; 17: 502-6.
45. Jarai Z, Kapocsi J, Farsang C, Detki K, Pados G, Sebestyen Z, et al. Effect of fluvastatin on serum lipid levels in essential hypertension. Orv Hetil 1996; 137: 1857-9.
46. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003; 25: 1107-22.
47. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001; 14: 1096-8.
48. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
49. Velussi M. Long term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Nutr Metab Cardiovasc Dis 2002; 12: 29-35.
50. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002; 16: 705-10.
51. Shinohara K, Shoji T, Kimoto E, Yokoyama H, Fujiwara S, Hatsuda S, et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005; 12: 205-10.
52. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999, 83: 1497-9.
53. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statis and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-55.
54. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study Schweiz Med Wochenschr 1998; 128: 272-7.
55. Magen E, Viskoper R, Mishal J, Priluk R, Berezovsky A, Laszt A, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004; 6: 742-6.
56. Kanbay M, Yildirir A, Bozbas H, Ulus T, Bilgi M. Muderrisoglu H, et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 2005; 27: 297-303.
57. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005; 46: 310-5.
58. Corpataux JM, Naik J, Porter KE, London NJ. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res 2005; 129: 52-6.
59. Treasure CB, Klein JL, Weintraub WS, Talley JD, Sullabower ME, Kosinski AS, et al. Beneficial in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
60. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 97: 1126-31.
61. Laufs U, La Fata V, Plutzsky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
62. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutarylcoenzyme-A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.
63. Seeger H, Mueck AO, Lippert TH. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. Int J Clin Pharmacol Ther 2000; 38: 270-2.
64. 2+ current in the rat basilar artery. Pharmacol Toxicol 2003; 93: 128-34.
65. 2+ channels in rat islet beta-cells. Br J Pharmacol 1999; 126: 1205-13.
66. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 1896-901.
67. Ide H, Fujiya S, Aanuma Y, Agishi Y. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990; 12: 410-20.
68. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004; 148: 635-40.
69. Rubattu S, Volpe M, Enea I, Russo R, Romano M, Trimarco B. Influence of hypercholesterolemia on adrenal steroid metabolism and electrolyte balance in spontaneously hypertensive rats. Endocrinology 1993; 133: 2015-21.
70. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. Statins: another class of antihypertensive agents? J Hum Hypertens 2006; 20: 320-35.